SureTrader SureTrader
Home > Boards > Canadian > Biotechs >

Immuno Vaccine Inc. (IMMVF)

IMMVF RSS Feed
Add IMMVF Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 7/22/2016 11:52:20 AM - Followers: 4 - Board type: Free - Posts Today: 0
TSX-V: IMV
Immunovaccine is a biotechnology company focused on advancing cancer therapies and infectious disease vaccines based on its patented immune enhancement platform DepoVaxTM
Highlights
Advance cancer immune therapies designed to maintain patients in remission and improve survival Develop differentiated infectious disease vaccines to address unmet medical threats
Leverage DepoVaxTM as a potent and flexible product enabling platform through technology licenses and partnerships
Product Pipeline
Immunovaccine’s Patented Technology
DepoVaxTM is a vaccine delivery platform that creates a unique deposit at the site of injection. This forces the immune system to process the optimized vaccine over a longer period of time, producing strong and sustained immunity. Immunovaccine develops products based on this platform and licenses the use of the platform to other parties for specific applications.
Cancer Immunotherapy
Immune based therapies are expected to form the backbone of cancer treatments in the next decade. IMV’s lead cancer immune therapy DPX-Survivac is an immunotherapy designed to train CD8+ T cells of the immune system to recognize cancer cells containing survivin, a therapeutic target associated with the great majority of solid tumors and blood cancers. Our therapy has demonstrated robust and sustained CD8+ T cell responses against survivin in a Phase 1 trial with evidence of a clinical benefit that is potentially associated with the therapy. We are planning two large randomized Phase 2 clinical trials in ovarian cancer and glioblastoma.
Infectious disease vaccines
Having demonstrated the ability to produce rapid, strong and sustained immunity against several disease models, Immunovaccine has attracted government agencies and research organizations to apply the DepoVax technology to create new and improved infectious disease vaccines. A Respiratory Syncytial Virus (RSV) vaccine designed to protect the elderly from the deadly illness will begin clinical testing in 2014; a counter bioterrorism vaccine for Anthrax has shown the potential for single dose applicability in studies performed by the US National Institutes of Health. These vaccine candidates represent significant future commercial opportunities for IMV.
Immunovaccine’s Patented Technology
DepoVaxTM is a vaccine delivery platform that creates a unique deposit at the site of injection. This forces the immune system to process the optimized vaccine over a longer period of time, producing strong and sustained immunity. Immunovaccine develops products based on this platform and licenses the use of the platform to other parties for specific applications.
Cancer Immunotherapy
Immune based therapies are expected to form the backbone of cancer treatments in the next decade. IMV’s lead cancer immune therapy DPX-Survivac is an immunotherapy designed to train CD8+ T cells of the immune system to recognize cancer cells containing survivin, a therapeutic target associated with the great majority of solid tumors and blood cancers. Our therapy has demonstrated robust and sustained CD8+ T cell responses against survivin in a Phase 1 trial with evidence of a clinical benefit that is potentially associated with the therapy. We are planning two large randomized Phase 2 clinical trials in ovarian cancer and glioblastoma.
Infectious disease vaccines
Having demonstrated the ability to produce rapid, strong and sustained immunity against several disease models, Immunovaccine has attracted government agencies and research organizations to apply the DepoVax technology to create new and improved infectious disease vaccines. A Respiratory Syncytial Virus (RSV) vaccine designed to protect the elderly from the deadly illness will begin clinical testing in 2014; a counter bioterrorism vaccine for Anthrax has shown the potential for single dose applicability in studies performed by the US National Institutes of Health. These vaccine candidates represent significant future commercial opportunities for IMV.

Management
Albert Scardino
Executive Chairman
Marc Mansour, PhD
Chief Operating Officer
Kimberly Stephens, CA
Chief Financial Officer
Additional DepoVaxTM platform opportunities
Immunovaccine’s core technology is versatile and can be applied to vaccines against a broad range of diseases. The commercial license agreements with Zoetis (formerly Pfizer Animal Health) and the high profile research partnerships in place are a testament to the differentiation the DepoVaxTM technology provides.
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IMMVF
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#51   Hello! Is there anybody here? You'd think this Bugzzie75 07/22/16 11:52:20 AM
#50   a critical milestone for Immunovaccine, xr_biotech_consult 07/06/16 11:42:51 AM
#49   great News out: xr_biotech_consult 07/06/16 11:41:37 AM
#48   Initiates Zika Virus Vaccine Program xr_biotech_consult 03/03/16 12:43:02 PM
#47   soon knocks da 1$ xr_biotech_consult 07/20/15 12:53:31 PM
#46   its not an approval. Receives Orphan Drug Designation xr_biotech_consult 07/15/15 03:29:05 PM
#45   FDA APPROVAL wab2021 07/15/15 11:20:56 AM
#44   tiny little gem here, main listening is at xr_biotech_consult 07/08/15 12:29:18 PM
#43   Albert Scardino of Immunovaccine Inc. : xr_biotech_consult 07/08/15 12:27:09 PM
#42   IMMUNOVACCINE AND PHARMATHENE SIGN EXCLUSIVE WORLDWIDE LICENSE AGREEMENT xr_biotech_consult 07/08/15 12:24:20 PM
#41   Immunovaccine releases DPX-Survivac clinical results xr_biotech_consult 07/08/15 12:23:11 PM
#40   Immunovaccine Initiates Clinical Trial with DPX-RSV Vaccine xr_biotech_consult 07/08/15 12:21:59 PM
#39   Incyte and Immunovaccine team up in ovarian cancer xr_biotech_consult 07/08/15 12:20:04 PM
#38   L2's are thin. It has great potential. Sunnyjoe234 05/18/15 01:37:03 PM
#37   Seel, Please do let us know what someconcerns 03/06/14 07:55:42 PM
#36   Well that is intriguing. I think I need Seel 03/05/14 06:16:26 PM
#35   One trade, 50k. Somebody is buying all noretreat 03/05/14 01:18:53 PM
#34   Well that is certainly true. I am not Seel 03/04/14 07:19:14 PM
#33   But, then again with a volume of 4K Ovidius 03/04/14 02:47:39 AM
#32   That is quite a spike. I can't find Seel 03/03/14 06:54:02 PM
#31   Someone just picked up my shares for a noretreat 03/03/14 10:10:49 AM
#30   Oh my god - you are cracking me up! Seel 02/21/14 08:35:16 PM
#29   I would not want anyone to get the noretreat 02/21/14 07:07:28 PM
#28   No worries noretreat! It was a funny comment! Seel 02/21/14 07:01:46 PM
#27   That was not a serious comment, just in noretreat 02/21/14 06:53:40 PM
#26   I always (ALWAYS!) chase the women who think noretreat 02/21/14 06:29:10 PM
#25   Think you're going to get away from us Seel 02/21/14 04:59:01 PM
#24   There was a pending article by GratefulLife which TOB 02/21/14 04:12:54 PM
#23   Oh for ch****'s sake. Thought I may noretreat 02/21/14 03:10:45 PM
#22   all the usual suspects! Ha! You always get Seel 02/21/14 01:46:28 PM
#21   Yup, all the usual suspects caught in the TOB 02/20/14 10:09:53 PM
#20   Hmmmm? Interesting. Must look further. I own a TheDane 02/18/14 07:13:46 PM
#19   Well...we know where somebody's mind is tonight! Take Seel 02/11/14 10:15:58 PM
#18   Anyone knows why this is on the grey sheets? Lilpunch01 02/11/14 02:31:01 PM
#17   IMMVF, prefer not to post my article...in the Gratefullife 02/11/14 11:34:32 AM
#16   Hi Gratefull... Ovidius 02/11/14 03:25:38 AM
#15   WUZZZZZZZZZZZZUP SEEL ! BTW, I'm the CEO and wild4ctix 02/10/14 06:29:15 PM
#14   Wild in wild form! Always makes me smile! Seel 02/10/14 06:21:01 PM
#13   I think it's all about the grey thing Seel 02/10/14 06:20:23 PM
#12   Next time I will not mention articles until Gratefullife 02/10/14 12:48:12 PM
#11   No worries Pal....you had no control over that. wild4ctix 02/10/14 12:41:16 PM
#10   Wild, to my surprise I just heard from Gratefullife 02/10/14 12:37:13 PM
#9   Thanks GL. I appreciate your opinion. wild4ctix 02/10/14 12:31:07 PM
#8   Any time now on the article...I doubt any Gratefullife 02/10/14 11:48:54 AM
#7   Thanks Pal, we're all good. Should I JUMP wild4ctix 02/10/14 11:44:30 AM
#6   And you as well Wildman! Gratefullife 02/10/14 11:39:06 AM
#5   Thanks GL ! Hope you're well pal. wild4ctix 02/10/14 11:11:22 AM
#4   Grateful - do you know when your article Seel 02/09/14 07:22:09 PM
#3   Looking forward to the SA article. Would like Seel 02/09/14 06:52:22 PM
#2   Grateful - for what it's worth - 4 Seel 02/09/14 06:51:58 PM
PostSubject